TY  - JOUR
AU  - Karpinski, Madeleine J
AU  - Hoberück, Sebastian
AU  - Fendler, Wolfgang P
AU  - Civan, Caner
AU  - Bundschuh, Ralph A
AU  - Thomas, Christian
AU  - Bjartell, Anders
AU  - Trägårdh, Elin
AU  - Soeterik, Timo F W
AU  - Evangelista, Laura
AU  - Vondrak, Andrej
AU  - Rasul, Sazan
AU  - Forner, Laura
AU  - Giorgio, Andrea Di
AU  - Scholtissek, Helen
AU  - Miksch, Jonathan
AU  - Holzgreve, Adrien
AU  - Lanfranchi, Francesco
AU  - Rahbar, Kambiz
AU  - Hofman, Michael S
AU  - Rauscher, Isabel
AU  - Güven, Osman
AU  - Eiber, Matthias
AU  - Ayati, Narjess
AU  - Umutlu, Lale
AU  - Herrmann, Ken
AU  - Hadaschik, Boris
AU  - Emmett, Louise
TI  - Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry.
JO  - European urology
VL  - nn
SN  - 0302-2838
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2025-02240
SP  - nn
PY  - 2025
N1  - epub / brief report
AB  - The PRIMARY score was implemented in Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) version 2 to improve accuracy for the diagnosis of clinically significant prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography (PET). We reviewed overall survival (OS) for patients who underwent PSMA PET for initial staging to evaluate the prognostic value of PRIMARY in a large, international, multicenter cohort. The cohort comprised 1889 patients who underwent PSMA PET for initial staging of prostate cancer at investigator sites across Europe and Australia between 2012 and 2021. Hazard ratios (HRs) with 95
KW  - Overall survival (Other)
KW  - PRIMARY score (Other)
KW  - Positron emission tomography (Other)
KW  - Prostate cancer (Other)
KW  - Prostate-specific membrane antigen (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41168067
DO  - DOI:10.1016/j.eururo.2025.10.013
UR  - https://inrepo02.dkfz.de/record/305581
ER  -